
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
almost 25 years ago
Participating Facultyalmost 25 years ago
Acetaminophen Use in Patients Who Drink Alcohol: Current Study Evidencealmost 25 years ago
The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol





